Skip to main content

First Biodegradable Biocatalytic VascularTherapeutic Implants

Objective

"We aim to perform academic development of a novel biomedical opportunity: localized synthesis of drugs within biocatalytic therapeutic vascular implants (BVI) for site-specific drug delivery to target organs and tissues. Primary envisioned targets for therapeutic intervention using BVI are atherosclerosis, viral hepatitis, and hepatocellular carcinoma: three of the most prevalent and debilitating conditions which affect hundreds of millions worldwide and which continue to increase in their importance in the era of increasingly aging population. For hepatic applications, we aim to develop drug eluting beads which are equipped with tools of enzyme-prodrug therapy (EPT) and are administered to the liver via trans-arterial catheter embolization. Therein, the beads perform localized synthesis of drugs and imaging reagents for anticancer combination therapy and theranostics, antiviral and anti-inflammatory agents for the treatment of hepatitis. Further, we conceive vascular therapeutic inserts (VTI) as a novel type of implantable biomaterials for treatment of atherosclerosis and re-endothelialization of vascular stents and grafts. Using EPT, inserts will tame “the guardian of cardiovascular grafts”, nitric oxide, for which localized, site specific synthesis and delivery spell success of therapeutic intervention and/or aided tissue regeneration. This proposal is positioned on the forefront of biomedical engineering and its success requires excellence in polymer chemistry, materials design, medicinal chemistry, and translational medicine. Each part of this proposal - design of novel types of vascular implants, engineering novel biomaterials, developing innovative fabrication and characterization techniques – is of high value for fundamental biomedical sciences. The project is target-oriented and once successful, will be of highest practical value and contribute to increased quality of life of millions of people worldwide."

Field of science

  • /medical and health sciences/medical biotechnology
  • /medical and health sciences/basic medicine/medicinal chemistry
  • /natural sciences/chemical sciences/polymer science
  • /engineering and technology/industrial biotechnology/biomaterials
  • /medical and health sciences/clinical medicine/cardiology/cardiovascular diseases/arteriosclerosis
  • /medical and health sciences/medical biotechnology/medical bioproducts/implants

Call for proposal

ERC-2013-CoG
See other projects for this call

Funding Scheme

ERC-CG - ERC Consolidator Grants

Host institution

AARHUS UNIVERSITET
Address
Nordre Ringgade 1
8000 Aarhus C
Denmark
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 996 126
Principal investigator
Alexander Zelikin (Dr.)
Administrative Contact
Ulla Blach (Mrs.)

Beneficiaries (1)

AARHUS UNIVERSITET
Denmark
EU contribution
€ 1 996 126
Address
Nordre Ringgade 1
8000 Aarhus C
Activity type
Higher or Secondary Education Establishments
Principal investigator
Alexander Zelikin (Dr.)
Administrative Contact
Ulla Blach (Mrs.)